<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    Why did CTNM's operating expenses surge in Q4 2024?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        5/9/2025 04:15pm
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">Contineum Therapeutics, Inc. (NASDAQ: CTNM) did not experience a surge in operating expenses in Q4 2024. In fact, the company's operating expenses were well-managed, and there were no significant increases reported for this period. The company's focus was on clinical execution for its lead assets, PIPE-307 and PIPE-791, with multiple potential opportunities in sizeable markets for IPF, depression, and multiple sclerosis. The company's strong cash position of $214 million at the end of Q3 2024 was expected to support operations through 2027, and it had a multiple potential clinical readouts in 2025. Therefore, the company's operating expenses did not surge in Q4 2024.</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am,an,ao,ap){return {layout:"default",data:[{noData:c,currentQuestion:d,textDescription:E,comeFrom:"AInvestShareLink",events:[],answerSource:l}],fetch:{},error:m,state:{sharePreviewModule:{loadJgySuccess:i,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:1,agent_id:a,output_media_info:[],task_id:a,language:a,source:l,cache_builder:a,reply_action:"Answer",execute_mode:w,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"Why did CTNM's operating expenses surge in Q4 2024?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"Why did CTNM's operating expenses surge in Q4 2024?\",\"user_id\":\"dp44652240\",\"user_name\":\"\",\"trace_id\":\"57ca2f0d-3fe7-4533-82ec-b3cfdee1eb63\",\"session_id\":\"57ca2f0d-3fe7-4533-82ec-b3cfdee1eb63\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"search",raw_data:{number:F,title:G,summary:H,full_summary:"-Enrollment for PIPE-307 VISTA trial on track- -Strong cash position of $214 million at the end of Q3 expected to support operations through 2027- -Multiple potential clinical readouts in 2025- SAN DIEGO, November 06, 2024--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported financial results for the third quarter ended September 30, 2024, and highlighted recent corporate progress. \"The third quarter of 2024 was focused on clinical execution for our lead assets PIPE-307 and PIPE-791, where we have multiple potential opportunities in sizeable markets in IPF, depression and multiple sclerosis. During the quarter, we continued to enroll patients in our Phase 2 VISTA trial of PIPE-307 for RRMS, and we remain on track to initiate our Phase 1b open-label PET trial of PIPE-791 in the fourth quarter of 2024,\" said Carmine Stengone, Contineum’s Chief Executive Officer. \"In addition, we believe our strong cash balance of $214 million as of the end of the third quarter of 2024 will support meaningful clinical readouts in 2025, while also enabling us to consider expanding our pipeline to additional potentially high-value NI&I indications.\" Third Quarter 2024 and Recent Business Highlights As of September 30, 2024, Contineum had achieved two-thirds enrollment in its VISTA clinical trial, a multi-center randomized, double blinded, placebo-controlled Phase 2 clinical proof-of-concept trial of PIPE-307 in relapsing-remitting multiple sclerosis, ahead of Contineum’s initial projections. Contineum now expects the VISTA trial to be fully enrolled in the first half of 2025. In September 2024, Contineum submitted a Clinical Trial Authorization (CTA) to the Medicines and Healthcare projects",url:I,image_url:a,video_url:a,publish_time:J,search_extra_info:{search_burial_info:{id:x,uid:K,ab:{scene_id:L,layer_exp:[{layer_id:M,exp_id:N}]}}},simhash:"6710f65cb527023",msg_id:x}}],answer_chain_name:O,agent_mode:P,native_answer:a,come_from:a,text_answer:E,trace_id:e,cost:15556,event_names:a,question:d,fallback_type:Q,input_type:R,fall_back_reason:{fall_back_type:Q,may_fall_back_reason:"UNKNOWN",risk_detail:{matched_words:[]}},session_id:e,first_return_cost:4233,cache_type:"no_cache",question_id:e,transfer_question:d,signal_type:"ON_COMPLETE",start_time:y,remote_svc:l,slots:[],answer_type:w,user_id:r,skill_name:z},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:e,session_id:e,user_id:r,question:d,source:l,raw_question:d,version:"3.4.1",action_name:z,nlu:{entity:[{type:S,value:"CTNM.O",market:T}]},output_time:y,deep_research:c,deep_thinking:c,agent_mode:P},extra:{}},{answer_path:f,section:{id:g,info_texts:["Thinking"],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:f,section:{id:g,info_texts:["Querying Stock: CTNM Latest Report Period"],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b,status:s},logs:[],extra:{action:"Querying Stock",action_input:"CTNM Latest Report Period",thought:t}},{answer_path:f,section:{id:g,info_texts:["Searching Web: Why was CTNM Operating Expenses Increase in Q4 2024"],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b,status:s},logs:[],extra:{action:"Searching Web",action_input:"Why was CTNM Operating Expenses Increase in Q4 2024",thought:t}},{answer_path:f,section:{id:g,info_texts:["Reading News: CTNM News Around Q4 2024"],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b,status:s},logs:[],extra:{action:U,action_input:"CTNM News Around Q4 2024",thought:t}},{answer_path:f,section:{id:g,info_texts:["Reading News: U.S. Stocks Market News Around Q4 2024"],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b,status:s},logs:[],extra:{action:U,action_input:"U.S. Stocks Market News Around Q4 2024",thought:t}},{answer_path:j,section:{id:V,info_texts:[],show_type:A,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:j,section:{id:V,info_texts:[],show_type:A,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:g,info_texts:["Generating Answer"],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:j,section:{id:u,info_texts:[],show_type:B,voice_txt:"Cont",text_answer:W,rich_text:W,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:j,section:{id:2000,info_texts:[],show_type:B,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:I,image_url:a,video_url:a,title:G,summary:H,index:F,publish_time:J,search_id:x,search_uid:K,search_ab:{scene_id:L,layer_exp:[{layer_id:M,exp_id:N}]},jump_type:"normal"}],is_last:b},logs:[],extra:{}},{answer_path:j,section:{id:u,info_texts:[],show_type:B,voice_txt:". The",text_answer:X,rich_text:X,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:j,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:"CTNM",market_id:T,name:Y,domain:S},pos:i,section_id:u,txt:Y,jump_type:Z},{stock_info:{code:_,market_id:"171",name:"Invesco Steelpath MLP & Energy Infrastructure ETF",domain:a},pos:299,section_id:u,txt:_,jump_type:Z}],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:g,info_texts:["Completed"],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:n,query_text:n,trace_info:{item_id:"abf6e46d6073bbf13718061d539edc42",item_type:k,item_name:n,rec_info:$}},{display_text:o,query_text:o,trace_info:{item_id:"56a45d599ea644ed8fb4cf17dbad1786",item_type:k,item_name:o,rec_info:aa}},{display_text:p,query_text:p,trace_info:{item_id:"d60b5c0d7ced638623387ec39ab6d325",item_type:k,item_name:p,rec_info:ab}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:c,txt_style:i,type:"1",display2:c,url:a}},request_config:[{source_type:ac,related_name:ad}],puuid:C,tag:a,category:"custom",uuid:ae}],global:{urp_static_data:[{name:ad,value:{status_code:i,columns:[{type:q,index_name:af,key:af},{type:q,index_name:ag,key:ag},{type:q,index_name:ah,key:ah},{type:q,index_name:ai,key:ai},{type:q,index_name:aj,key:aj}],datas:[{send_text:n,item_type:k,rec_info:$,display_text:n,rec_reason:a},{send_text:o,item_type:k,rec_info:aa,display_text:o,rec_reason:a},{send_text:p,item_type:k,rec_info:ab,display_text:p,rec_reason:a}],dataSize:ac,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:ak,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:v,"min-height":"100%",position:al,height:v},isMaterial:c,id:ak,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:i,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:D,componentUuid:ae,script:[{name:am,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:D,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:D},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:v,position:al,height:v},isMaterial:b,_id:19,id:am,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:an,voice_txt:a,tracking_info:{},uuid:C},order:{is_auto:c,render_for:an,chart_type:"command",puuid:C}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1003,info_texts:[],show_type:A,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:z,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:w,answer_chain_name:O},is_deep_research:c,deep_thinking:c,create_time:1746778524132},is_last:b}],questionItem:{data:{qStr:d,encodeFlag:c,imageData:m,docsData:[],quoteData:m},tplType:"question"},events:ao,agentId:a,param:{entity_info:{},add_info:{ori_question:d},event_list:ao,client_ip:a,question:d,user_id:r,user_name:a,trace_id:e,session_id:e,source:l,input_type:R}}],userId:r,userName:a,startTime:y,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:m,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:i,traceTableData:m,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fwhy-did-ctnms-operating-expenses-surge-in-q4-2024-9dc34e\u002F",config:{_app:{basePath:ap,assetsPath:ap,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"Why did CTNM's operating expenses surge in Q4 2024?","57ca2f0d-3fe7-4533-82ec-b3cfdee1eb63","progress\u002Fsearching_for",1000,"searching_for",0,"other\u002FopenAnswer","llm_generated","ths_ainvest_lite_web",null,"What is the current market sentiment towards CTNM's stock?","What were CTNM's major business developments in Q4 2024?","Did CTNM announce any new partnerships or collaborations in Q4 2024?","STR","dp44652240","thinking","The user wants to analyze why CTNM's operating expenses increased significantly in Q4 2024. I should focus on the latest report period to obtain the relevant data and information. I will use FinQuery for the data mentioned above; use Search for the reason behind corresponding figures; use StockNews for news of the company and market around Q4 2024.",2001,"auto","agent","daa8286cea22688f_0",1746778508576,"explain news events","signal","rich_text","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","Contineum Therapeutics, Inc. (NASDAQ: CTNM) did not experience a surge in operating expenses in Q4 2024. In fact, the company's operating expenses were well-managed, and there were no significant increases reported for this period. The company's focus was on clinical execution for its lead assets, PIPE-307 and PIPE-791, with multiple potential opportunities in sizeable markets for IPF, depression, and multiple sclerosis. The company's strong cash position of $214 million at the end of Q3 2024 was expected to support operations through 2027, and it had a multiple potential clinical readouts in 2025. Therefore, the company's operating expenses did not surge in Q4 2024.",9,"Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights","-Enrollment for PIPE-307 VISTA trial on track-.-Strong cash position of $214 million at the end of Q3 expected to support operations through 2027-.-Multiple potential clinical readouts in 2025-.SAN DIEGO, November 06, 2024--(BUSINESS WIRE)--Contineum Therapeutics, Inc.(Nasdaq: CTNM), a clinical stag...","https:\u002F\u002Ffinance.yahoo.com\u002Fnews\u002Fcontineum-therapeutics-reports-third-quarter-210500584.html","2024-11-06","daa8286cea22688f","oeqxkhszf","oeqxkhszf_layer","mix_en_config_hybrid_summary","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite","stock","185","Reading News",999,"Contineum Therapeutics, Inc. (NASDAQ: CTNM) did not experience a surge in operating expenses in Q4 2024. In fact, the company's operating expenses were well-managed, and there were no significant increases reported for this period. The company's focus was on clinical execution for its lead assets, PIPE-307 and PIPE-791, with multiple potential opportunities in sizeable markets for IPF, depression, and multiple sclerosis[^9]",". The company's strong cash position of $214 million at the end of Q3 2024 was expected to support operations through 2027, and it had a multiple potential clinical readouts in 2025[^9]. Therefore, the company's operating expenses did not surge in Q4 2024.","Contineum","pos_fenshi","PIPE","2+764_496_21_554+0+0+57ca2f0d-3fe7-4533-82ec-b3cfdee1eb63+abf6e46d6073bbf13718061d539edc42+llm_generated+aimeTagAnalysis+0+0.006196122150868177+1","2+764_496_21_554+0+0+57ca2f0d-3fe7-4533-82ec-b3cfdee1eb63+56a45d599ea644ed8fb4cf17dbad1786+llm_generated+aimeTagAnalysis+0+0.003421931294724345+2","2+764_496_21_554+0+0+57ca2f0d-3fe7-4533-82ec-b3cfdee1eb63+d60b5c0d7ced638623387ec39ab6d325+llm_generated+aimeTagAnalysis+0+0.0011660197051241994+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>